Presentations on the 2019 Debates and Didactics in Hematology/Oncology - prIME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Presentations on the 2019 Debates and Didactics in Hematology/Oncology

Winship Cancer Institute Annual Cancer Conference

Not a member of My prIME? Join now for instant access.

The Debates and Didactics in Hematology/Oncology Conference was a meeting of faculty across a broad landscape of tumor types. These experts assembled to discuss current and emerging treatment options in solid tumors and hematologic malignancies. Furthermore, they participated in debates regarding selection of optimal therapy across various malignancies. These downloadable slides are designed to allow participants to see the main ideas conveyed in the didactic and debate portions of this meeting.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Aug 19, 2019

Expiration Date

Aug 19, 2020

Breast/Lymphoma

Triple-Negative Breast Cancer: An Emerging Role for Immunotherapy
Jane Lowe Meisel, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Genomic Testing for Lymph Node-Positive Breast Cancer? Why Not?
Cletus Arciero, MD, FACS
Winship Cancer Center of Emory University, Atlanta, Georgia

Should All Women With Hormone-Positive Lymph Node-Positive Breast Cancer Undergo Genomic Testing? NO
Keerthi Gogineni, MD, MSHP
Winship Cancer Center of Emory University, Atlanta, Georgia

Using Residual Disease to Guide Adjuvant Systemic Therapy Decisions in the Post-Neoadjvuant Setting
Elisavet Paplomata, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Is There a Role for Proton Therapy in Breast Cancer?
Mylin A Torres, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Concept and Challenges of Biosimilar in Breast Cancer
Manali Bhave, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Approach to Managing MDS: Case-Based Instruction
Marth L Arellano, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Should All Patients < 60 Have a BTK Inhibitor As Part of First-Line Therapy? YES!
Susan O’Brien, MD
University of California, Irvine, California

All Young Patients With CLL Do NOT Need BTK Inhibitors
Jonathon B Cohen, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Incorporating Targeted Agents Into AML Therapy
William Blum, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Comprehensive Multi-Disciplinary Care Plans for Cutaneous T-Cell Lymphomas
Mary Jo Lechowicz, MD
University of  Nebraskas Medical Center, Omaha, Nebraska

Novel Agents in Cutaneous T-Cell Lymphoma
Pamela Allen, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Early Relapse of Follicular Lymphoma
Amelia Langston, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

How Should You Treat Patients With Early Relapsed of FL? Clinical Trial
Christopher Flowers, MD, MS
Winship Cancer Center of Emory University, Atlanta, Georgia

Cellular Therapies in Follicular Lymphoma
Jonathon Cohen, MD, MS
Winship Cancer Center of Emory University, Atlanta, Georgia

Current, Practical Controversies in Managing Patients With Diffuse Large B-Cell Lymphoma
James Armitage, MD, FASCO
University of Nebraskas Medical Center, Omaha, Nebraska

What Is the Optimal Therapy for Hodgkin Lymphoma at Diagnosis and Relapse?
Kristie A Blum, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Waldenström Macroglobulinemia: New Options
Leonard T Heffner, Jr, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Adoptive T-Cell Therapy for Cancer: Does Raw Material Matter?
Daniel J Powell, Jr, PhD
Winship Cancer Center of Emory University, Atlanta, Georgia

Back to Top

Lung/Head & Neck/Myeloma

High PD-L1 NSCLC: Immunotherapy Alone? YES
Conor Steuer, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

What Do I Recommend for Stage IV Patients With High PD-L1 Expression? Chemo/IO
Rathi Pillai, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Role and Timing of Immune Therapy in SCLC
Taofeek Owonikoko, MD, PhD
Winship Cancer Center of Emory University, Atlanta, Georgia

Update on Targeted Therapy for Advanced NSCLC
Suresh Ramalingam, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Immunotherapy Combination Approaches in NSCLC
Rathi Pillai, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Integration of Immunotherapy With RT
Walter J. Curran, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Updates on Immunotherapy in SCCHN
Nabil Saba, MD, FACP
Winship Cancer Center of Emory University, Atlanta, Georgia

Salvage Surgery Is the Standard of Care for Locally Recurrent SCCHN
Mark W El-Deiry, MD, FACS
University of California, Irvine, California

Is Salvage Surgery the Optimal Standard of Care for Locally Recurrent HNSCC?
Nabil Saba, MD, FACP
Winship Cancer Center of Emory University, Atlanta, Georgia

Should Monoclonal Antibodies Be Added to Front-Line Myeloma Treatment? (Yes)
Ajay K Nooka, MD, MPH, FACP
Winship Cancer Center of Emory University, Atlanta, Georgia

In July 2019, Should We Use a CD38 Antibody Upfront?
Craig Hofmeister, MD, MPH
Winship Cancer Center of Emory University, Atlanta, Georgia

Smoldering MM
Sagar Lonial, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

How to Approach Relapsed Myeloma
Kenneth Anderson, MD
Harvard Medical School Dana-Farber Cancer Institute, Boston, Massachusetts

Translational Science in Multiple Myeloma
Lawrence H Boise, PhD
Winship Cancer Center of Emory University, Atlanta, Georgia

Atypical CML: Diagnosis and Treatment
Rebecca B Klisovic, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Amyloidosis: 2019 Update
Jonathan L Kaufman, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Incorporation of Immunotherapy Into ALL Therapies
Hagop Kantarjian, MD
University of Texas MD Anderson Cancer Center, Houston, Texas

Transplant and Cellular Therapy for Relapsed B-ALL: NOT an Either/or Proposition
Amelia Langston, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Back to Top

Leukemia/GI/Melanoma/Other Tumor Types

Is Adjuvant Therapy in Resected Cholangiocarcinoma Standard of Care? YES
Bassel F El-Rayes, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Is Adjuvant Therapy in Resected Cholangiocarcinoma Standard of Care? No
David A Kooby, MD, FACS
Winship Cancer Center of Emory University, Atlanta, Georgia

Systemic Therapy for Hepatocellular Cancer: Is There a Preferred Sequence?
Christina Wu, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Adjuvant Therapy for Pancreatic Cancer: Is mFOLFIRINOX the New Standard?
Bassel F El-Rayes, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Personalized Medicine in Metastatic Colon Cancer: Are We There Yet?
Christina Wu, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Understanding the RCT Data From CRS/HIPEC for Colorectal Cancer: An Opportunity?
Charles A Staley, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Translational Science Improves Gastrointestinal Tumor Therapy
Gregory B Lesinski, PhD, MPH
Winship Cancer Center of Emory University, Atlanta, Georgia

Multidisciplinary Approach to Metastatic Melanoma: What Role Should Surgery Play?
Michael Lowe, MD, MA, FACS
University of California, Irvine, California

Upfront Systemic Therapy or Surgery for Oligometastatic Melanoma: Clearly the Answer Is Systemic Therapy
Ragini Kudchadkar, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Neoadjuvant Therapy in Stage III Melanoma: Is it Ready for Primetime?
Michael Lowe, MD, MA, FACS
Winship Cancer Center of Emory University, Atlanta, Georgia

What Is the Appropriate Front-Line Therapy for Melanoma?
Ragini Kudchadkar, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumor Treatment
Walid Shaib, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Glioblastoma: What to Do Now?
Manmeet Ahluwalia, MD, FACP
Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio

Updates in Management of Cancer-Associated Thrombosis
Christine L Kempton, MD, MSc
Emory University School of Medicine, Atlanta, Georgia

What to Be Sure to Do for Your Sickle Cell Patients
Morgan L McLemore, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Phase I Trials and Their Role in Therapy: The Winship Experience
R Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Winship Cancer Center of Emory University, Atlanta, Georgia

Back to Top

Genitourinary/Gynecologic

What Is New in Ovarian Cancer
Elisavet Paplomata, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Not Just Carbo/Taxol Anymore: New Options for Metastatic Endometrial Cancer
Jane Lowe Meisel, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Management of Oligometastatic Prostate Cancer: No Salvage Therapy
Christopher Filson, MD, MS
Winship Cancer Center of Emory University, Atlanta, Georgia

Management of Oligometastatic Prostate Cancer: Definitely YES for Salvage Therapy
Mehmet Asin Bilen, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Therapeutic Approaches to the Platinum-Ineligible Urothelial Cancer Patient
Bradley C Carthon, MD, PhD
Winship Cancer Center of Emory University, Atlanta, Georgia

Prostate Cancer Therapy: What Is the Present State of the Art?
Mehmet Asin Bilen, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Current First-Line Therapy for Advanced ccRCC: A Rapidly Changing Paradigm
Michael B Atkins, MD
Georgetown University Medical Center, Washington DC

Back to Top

After successful completion of this educational activity, participants should be able to:

  • Evaluate the risks and benefits of emerging therapies and novel treatment strategies for patients with solid tumors and hematologic malignancies, as well as the practical utility of these approaches based on recent clinical data
  • Apply best practices regarding the treatment of patients with cancer, including integration of novel therapeutic approaches and individualization of care
  • Appropriately integrate multimodality therapy and multidisciplinary care to improve the management of patients with cancer
This educational activity is supported by a grant from AstraZeneca.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by Postgraduate Institute for Medicine and prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is jointly provided by Postgraduate Institute for Medicine, prIME Oncology, and Winship Cancer Institute of Emory University.

Disclosure Information

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Ahluwalia has disclosed royalties from Wiley. He also disclosed consulting fees from AbbVie, Bayer, Elsevier, Flatiron, Karyopharm, Varian Medical Systems, and VBI Vaccines. He also discloses contracted research for AbbVie, AstraZeneca, Bayer, Bristol-Myers Squibb, Incye, Merck, Novocure, and Pharmacyclics.  He disclosed ownership interest (less than 5%) in Doctible and Mimivax.

Dr Anderson has disclosed that he has received consulting fees from Bristol-Myers Squibb, Janssen, Celgene, Gilead, Precision Biosciences, Millennium, and Sanofi-Aventis. He also disclosed ownership interest (less than 5%) as scientific founder of Oncopep, Inc. and C4 Therapeutics.

Dr Armitage disclosed consulting fees from Ascentage, Oncology Analytics, Partner Therapeutics, and Samus Therapeutics.

Dr Atkins has disclosed consulting fees from Arrowhead, Bristol-Myers Squibb, Eisai, Exelixis, Merck, Novartis, Roche, and X4P. He also discloses contracted research for Bristol-Myers Squibb and Roche.

Dr Bilen disclosed consulting fees from Exelixis, Genomic Health, Nektar, and Sanofi. He also disclosed contracted research for AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech/Roche, Incyte, Nektar, Peleton, Pfizer, and Tricon Pharmaceuticals.

Dr Kristie Blum has disclosed contracted research (funding provided to institution) from Acerta, Seattle Genetics/ACCRU, BMS, and Pharmacyclics/Janssen.

Dr William Blum disclosed contracted research for Boehringer Ingelheim, Daiichi Sankyo, FORMA, and the Leukemia & Lymphoma Society.

Dr Boise has disclosed that he has received consulting fees from AstraZeneca.

Dr Cohen has disclosed that he has received consulting fees from Seattle Genetics and Janssen. He has disclosed contracted research from AstraZeneca, BMS, Takeda, Novartis, LAM, BioInvent, LRF, ASH, Genentech, and Seattle Genetics.

Dr Curran has disclosed that he has received consulting fees from Astra Zeneca and Bristol-Meyers Squibb.

Dr El-Rayes disclosed consulting fees from Bayer, Exelixis, and Novartis. He also disclosed contracted research for Bayer, BBI, Bristol-Myers Squibb, Cleave Biosciences, Five Prime Therapeutics, Hoosier Cancer Research Network, ICON, Merck, and Taiho.

Dr Flowers disclosed consulting fees from AbbVie, AstraZeneca, Bayer, BeiGene, Celgene, Denovo Biopharma, Gilead, OptumRX, Karyopharm, Pharmacyclics, Janssen, and Spectrum. He also disclosed contracted research for AbbVie, Acerta, BeiGene, Burroughs Wellcome Fund, Celgene, Eastern Cooperative Oncology Group, Gilead, Genentech/Roche, Janssen Pharmaceutical, Millenium/Takeda, Pharmacyclics, National Cancer Institute , TG Therapeutics, and the V Foundation.

Dr Gogineni has disclosed that she has received consulting fees from Eisai.

Dr Harvey disclosed consulting fees from Bristol-Myers Squibb, Genentech, GlaxoSmithKline, and Takeda.  He also discloses contracted research (funds to institution which support salary) for AbbVie, Amgen, Arqule, AstraZeneca, Bristol-Myers Squibb, Boston Biomedical, Calithera, Celgene, Cleave, Corvus, Eli Lilly, Five Prime Therapeutics, Genmab, Halozyme, Ignyta, Incyte, Merck, Nektar, Pfizer, Regeneron, Rgenix, Sanofi, Syndax, Takeda, Tesaro, Vertex, and Xencor.

Dr Hofmeister has disclosed that he has received consulting fees from Nektar, Karyopharm, Oncopeptides, and Celgene.

Dr Kantarjian has disclosed contracted research for AbbVie, Agios, Amgen, Ariad, Astex, Bristol-Myers Squibb, Cyclacel, Daiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, and Pfizer.  He has also disclosed receipt of other honoraria from AbbVie, Actinium, Agios, Amgen, Immunogen, Orsinex, Pfizer, and Takeda.

Dr Kaufman disclosed consulting fees from AbbVie, Bristol-Myers Squibb, Janssen, and Takeda. He also disclosed membership on an advisory committee or review panel for Incyte.

Dr Kempton has disclosed that she has received consulting fees from Octapharma, Genentech, and Pfizer.

Dr Klisovic has disclosed that she is a member of an advisory committee or review panel for Novartis.

Dr Kudchadkar has disclosed that she has received consulting fees from BMS, Array, and Novartis. She has disclosed contracted research from Merck and Regeneron.

Dr Lechowicz has disclosed that she has received consulting fees from Kyowa Kirin.

Dr Lesinski has disclosed that he has received consulting fees from ProDa Biotech LLC. He has disclosed contracted research from Bristol Myers Squibb, Inc.; Vaccinex, Inc.; Boerhinger, Ingelheim, Inc.; and Merck and Co.,Inc.

Dr Lonial discloses that he has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Novartis, and Takeda.

Dr Meisel has disclosed that she has received consulting fees from Pfizer and Puma.

Dr Nooka has disclosed that he has received consulting fees from Adaptive, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Spectrum, and Takeda.

Dr O’Brien has disclosed that she has received consulting fees from AbbVie; Alexion; Amgen; Aptose Biosciences, Inc.; Astellas; Celgene; Eisai; Gilead; GlaxoSmithKline; Janssen Oncology; Pfizer; Pharmacyclics; Sunesis; TG Therapeutics; Vaniam Group LLC; and Verastem. She has also received research support from Acerta, Gilead, Kite, Pfizer, Pharmacyclics, Regeneron, Sunesis, and TG Therapeutics.

Dr Owonikoko has disclosed that he has received consulting fees from AbbVie, Bristol-Meyers Squibb, AstraZeneca, and Amgen.

Dr Paplomata has disclosed research support from Genentech, Hoosier Cancer Research Network (funding to institution), Merck, Novartis, Seattle Genetics. She also disclosed receipt of dinner from Genentech, Novartis, and Tesaro.

Dr Pillai has disclosed contracted research from Bristol-Myers Squibb.

Dr Powell has disclosed a milestone payment from Novartis and sponsored research funding from Tmunity. He also disclosed licensed CAR constructs to Tmunity. He also disclosed patents in CAR T-cell technologies and TIL therapy. He further disclosed receipt of consulting fees from Bellicum, Iovance, Neon, and Tmunity. He disclosed contracted research for Hulow, Incyte, Lilly, and Medimmune. He disclosed ownership interest (less than 5%) in Atara Bio.

Dr Ramalingam has disclosed that he has received consulting fees from Amgen, AbbVie, BMS, Celgene, Lilly, Genentech, Merck, AstraZeneca, Takeda, and Loxo.

Dr Saba has disclosed that he has received consulting fees from Merck, GlaxoSmithKline plc, Lilly, BMS, and Cue Biopharma.

Dr Shaib has disclosed that he has received consulting fees from Ipsen and Blue Prints. He has disclosed contracted research from Eli Lilly, Basilea Pharmaceutica Ltd., Boston Biomedical, and Lexicon.

Dr Steuer has disclosed that he has received consulting fees from AbbVie, Armo, Bergen BIO, Eli-Lilly. He has disclosed contracted research from Vaccinex.

Dr Wu has disclosed contracted research from FLX Bio, Vaccinex, Bristol-Meyers Squibb, Boston Biomedical, Lycera, and Symphogen.

The following faculty members have no relevant financial relationships to disclose:

Dr Allen

Dr Arciero

Dr Arellano

Dr Berger

Dr Bhave

Dr Carthon

Dr El-Deiry

Dr Filson

Dr Heffner

Dr Kooby

Dr Langston

Dr Lowe

Dr McLemore

Dr Pippas

Dr Simmons

Dr Staley

Dr Szabo

Dr Torres

Postgraduate Institute for Medicine planners and managers have disclosed no relevant financial relationships.

The employees of prIME Oncology have disclosed no relevant financial relationships.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.